TU2218, a novel ALK5/VEGFR2 dual inhibitor, overcomes tumor endothelial cell anergy and enhances anti-PD1 immunotherapy efficacy
TU2218
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: TU2218, a novel ALK5/VEGFR2 dual inhibitor, overcomes tumor endothelial cell anergy and enhances anti-PD1 immunotherapy efficacy ### Output: TU2218